Back to results
US 2021/0228505 A1Published application
Method of treating major depressive disorder
AssigneeClexio Biosciences Ltd.
InventorsElena Kagan, Gina Pastino
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for safe and efficacious administration of esketamine.
Claims20
A method of treating major depressive disorder (MDD) in a human patient in need thereof comprising orally administering once daily to said patient for at least 28 days, an oral dosage form comprising 40 mg of esketamine.
A method of treating major depressive disorder (MDD) in a human patient in need thereof wherein the human patient orally self-administers once daily for at least 28 days an oral dosage form comprising 40 mg of esketamine.
Dependencies are inferred from the claim text.